** Dyne Therapeutics' DYN.O shares down 12.6% premarket to $8.32, lowest since mid-Apr, after overnight follow-on priced
** Co, which focuses on neuromuscular diseases, late Mon said sold ~24.2 mln shares at $8.25 for $200 mln gross proceeds
** Offering priced at 13.3% discount to last sale
** It intends to net offering proceeds to fund ongoing clinical development of its product candidates, per the prospectus
** Also late Mon, Waltham, Massachusetts-based firm said it secured up to $275 mln in debt financing from Hercules Capital
** Morgan Stanley, Jefferies, Stifel and Guggenheim are jt bookrunners for the offering
** With ~113.7 mln shares outstanding, DYN has $1.1 bln market cap
** On Jun 17, DYN shares fell 21% to close at $10.86 after co revised timelines for its genetic disorder therapy following meeting with the FDA
** Through Mon, stock has shed ~60% YTD
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。